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A B S T R A C T
Concerning the important differences in the ethiopathology of hepatocelular carcinomas (HCC) in humans and dogs,
our work describes the expression of epidermal growth factor receptor (EGFr), cytokeratine 19 (CK19), vascular endothe-
lial growth factor (VEGF) and transforming growth factor beta receptor (TGFb-r) in tumors arising in both species. In-
vestigation included 25 cases of human and 8 cases of dog tumors. All human cases were noted in cirrhotic livers, while
in dogs the tissue adjacent to tumor was not changed. In humans in two cases hepatitis B virus (HBV) and in one case
hepatitis C virus (HCV) were determined. Investigation showed lack of TGFb-r reaction in six cases of canine HCC, while
in humans only one case was negative. In most tumors specific hepatocyte antigen Hepatocyte Paraffin 1 marker (Hep Par
1) was mainly positive with markedly decreased reaction compared to the normal hepatocytes, while cytokeratine 19 for
billiary epithelium was negative. The result of our investigation rise the question about the possible role of tumor sup-
pressor gene TGFb-r in the development of HCC in dogs and in the same time emphasizes its importance in human dis-
eases.
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Introduction
Hepatocellular carcinoma (HCC) constitutes approxi-
mately 5.4% of cancers in humans, but in some parts of
the world (Asia and Africa) this tumor is much more
common1,2. In animals HCC occurs in numerous species
but it seems that they are more common and dogs and
cats than ruminants, pigs and horses. However, com-
pared to humans these tumors are much less common
and the incidence in dogs has been reported to be less
than 1% of all neoplasms3. Concerning the pathogenesis
it is well known that cirrhosis and viral infections (HBV
/hepatitis B virus/ and HCV /hepatitis C virus) has major
influence on HCC occurrence in humans1. In dogs the sit-
uation is quite opposite. Namely, »hepatobiliary tumors
in domestic animals are not obvious successors to ante-
cedent liver disease«4. It also should be noted that the
prevalence of spontaneous HCC is very different between
humans, rats, mice and dogs and that the prevalence of
HCC is higher in mice and rats than in humans5. Despite
obvious very different pathogenesis of the HCC in dogs
and humans, histopathological types of tumors are very
similar. Namely, in both species there are trabecular,
pseudoglandular or adenoid and solid or poorly differen-
tiated forms of tumors. In humans there is one more type
or fibrolamellar carcinoma1,3.
Concerning the liver mitogens, it is well known that
epidermal growth factor (EGF) and transforming growth
factor alpha (TGFa) are important hepatocytic mito-
gens6, vascular endothelial growth factor (VEGF) is very
important for tumor angiogenesis7, while p53 and trans-
forming growth factor beta (TGFb) with its receptors
(TGFb-r) are tumor suppressor genes8,9.
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The present study evaluated cellular reactivity and lo-
calization of epidermal growth factor receptor (EGFr),
p53, VEGF and TGFb-r in human and dog HCC. Tumor
diagnosis was establish using histopathological evalua-
tion, and immunohistochemical reactivity to cytokeratine
19 (CK19) (for cholangiocellular carcinomas) and hepato-
cyte antigen Hep Par1 (for HCC)10. The results of the
study could be helpful in determining existing species
differences in tumor development.
Materials and Methods
Selection of human and canine patients
Liver specimens with HCC were obtained from 25 hu-
mans and 8 dogs. Human cases were biopsies (with HBV
and HCV status) while animal cases were obtained on
necropsy during the years 2005–2008. Histopathological
analysis was performed using hematoxylin and eosin
(HE) staining.
Immunohistochemistry study
Liver specimens were fixed in 10% neutral-buffered
formalin and subsequently embedded in paraffin. Serial
4mm thick sections were acquired from each paraffin
block. Paraffin sections of all specimens were deparaffi-
nised in xylene and then rehydrated through graded al-
cohol. Endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide for 10 min. The following anti-
bodies were used for immunohistochemistry: anti-hu-
man hepatocyte, anti – human Cytokeratin 19, anti –hu-
man Epidermal Growth Factor Receptor, anti – human
Vascular Endothelial Growth Factor monoclonal mouse
antibodies (Dako Glostrup, Denmark) and mouse mono-
clonal Transforming Growth Factor Beta Receptor anti-
body (Novocastra). Immunostaining was performed by
the avidin biotin peroxidase complex (ABC) method us-
ing LSAB+, Dako, Glostrup, Denmark kit. The immuno-
staining results were interpreted using a light micro-
scope with 40x objective. In each specimen we analysed 3
microscope fields in the most positive area of the tumor
(hot spot). Positivity was assessed by a semiquantitative
method on a scale from 0 to 3.
Results
Histopathology
In humans liver cirrhosis was seen in all cases of HCC.
In three patients viral hepatitis was determined i.e. two
cases of HBV and one case of HCV infection. Histopatho-
logical tumor patterns were of mixed type, namely in the
same tumor various types were seen, predominately tra-
becular and pseudoglandular types. HCC in dogs was in 6
cases trabecular type, in two solid type, and no signs of
some other liver diseases were noted. The diagnosis of
HCC was additionally established with Hep Par 1 and
CK19 immunohistochemical reaction of the tumor tissue.
Immunohistochemistry study
The results of immunohistochemical staining are
shown in Tables 1 and 2 for human and dog tumors re-
spectively. EGFr was positive in 18 and negative in 5 hu-
man cases. Reaction score was in most instances 3, and
the reaction was visible as cytoplasmic granular mate-
rial. The same pattern was seen in dogs in which in five
cases there was positive staining while three were nega-
tive. The expression of VEGF was even more pronounc-
ed, namely only three human tumors were negative and
22 were positive with predominately largest score. In
dogs, reaction was less apparent compared to humans
but positive reaction was present in five tumors. Also the
reaction score was less intense. Staining was cytoplasmic
and finely granular. Most apparent differences were not-
ed in TGFb-r staining. Namely, in human HCC predomi-
nately highly positive reaction was seen in almost all tu-
mors (24) and only in one case there were no expression.
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TABLE 1
IMMUNOHISTOCHEMICAL STAINING IN PARAFFIN EMBEDDED
HUMAN HEPATOCELLULAR CARCINOMAS WITH ANTIBODIES











1. 0 0 0 2
2. 2 0 3 3
3. 2 0 3 3
4. 1 0 1 2
5. 0 3 0 0
6. 3 0 2 3
7. 3 0 3 3
8. 3 0 3 3
9. 2 0 3 3
10. 1 0 3 3
11. 0 0 2 3
12. 0 0 3 3
13. 3 1 3 3
14. 3 1 3 3
15. 1 2 1 2
16. 0 3 3
17. 0 3 3
18. 3 0 3 3
19. 3 3 3 3
20. 0 3 0 1
21. 3 0 3 3
22. 3 0 3 3
23. 3 2 3 2
24. 3 1 1 3
25. 3 3 3 3
Score – 0-3, EGF-3 – epidermal rowth factor receptor, CK19 –
cytokeratine 19, VEGF – vascular endotrhelial growth factor,
TGFb-r – transforming growth factor beta receptor
The intensity score was predominately high not only in
tumor but also in adjacent cirrhotic liver tissue (Figure
1). The staining was finely granular and cytoplasmic. On
the contrary, in dogs in six tumors there was no reaction
at all, and positive tumor cells were noted only in two
cases. It is also interesting that normal hepatocytes in
the tissue adjacent to tumor show a positive reaction
(Figure 2). Reaction was cytoplasmic but coarsely granu-
lar. CK 19 immunostaining was negative in all cases,
while Hep Par 1 was markedly less apparent in tumor
comparing to the normal liver tissue (Figure 3) and in
two cases of solid type the reactions were negative.
Discussion
TGFb and its receptors have been implicated as tu-
mor suppressor genes and important antimitogenic fac-
tors in the liver and gastrointestinal tract. It was shown
that inactivation of its signaling in hepatocytes results in
an increased proliferative response after partial hepatec-
tomy in knockout mice8. Also, it is well known that its in-
activation leads to development of the pancreatic carci-
nomas and colonic cancers11. Generally, TGFb is a growth
inhibitor for most epithelial cell types and for leuko-
cytes12 and because of that loss of its receptors frequently
occurs in various tumors as it was earlier mentioned.
However, in the literature we were not able to find this
concerning the HCC in dogs. It may be supposed that loss
of TGFb-r plays a crucial role in carcinogenesis of this tu-
mor especially because of the facts that adjacent hepato-
cytes have normal reactivity and that this tumor devel-
ops in apparently normal liver tissue. This finding also
has important impact on HCC in humans and probably
provides new insight in its development. The role of
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TABLE 2
IMMUNOHISTOCHEMICAL STAINING IN PARAFFIN EMBEDDED
DOG HEPATOCELLULAR CARCINOMAS WITH ANTIBODIES TO











1. 0 0 0 0
2. 3 0 3 0
3. 1 0 1 0
4. 3 0 3 2
5. 0 0 0 0
6. 2 0 1 0
7. 0 0 0 0
8. 3 0 3 3
Score – 0-3, EGF-3 – epidermal rowth factor receptor, CK19 –
cytokeratine 19, VEGF – vascular endotrhelial growth factor,
TGFb-r – transforming growth factor beta receptor
Fig. 1. Liver, human. HCC and cirrhosis. TGFb-r expression in
tumor cells as well as in hepatocytes. Hematoxylin counterstain.
Bar 20 mm.
Fig. 2. Liver, dog. HCC. Granular staining with TGFb-r of the
compressed hepatocytes on the right and lack of reaction of the
tumor tissue on the left side of the figure. Hematoxylin counter-
stain. Bar 20 mm.
Fig 3. Liver; dog. HCC. Some tumor cells and individual hepato-
cytes react with Hep Par 1. Hematoxylin counterstain. Bar 20 mm.
VEGF and EGF receptor in tumor growth and progression
is well known and their expression is widely used in the es-
timating degree of malignancy in various tumors6,13,14. In
this work their expression was very similar to these liter-
ature data.
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KOMPARATIVNA ANALIZA HEPATOCELULARNIH KARCINOMA LJUDI I PASA
S A @ E T A K
S obzirom na zna~ajne razlike etiopatologije hepatocelularnih carcinoma (HCC) ljudi i pasa, na{ rad opisuje ekspre-
siju receptora epidermalnog faktora rasta (EGFr), citokeratina 19 (CK19), faktora rasta podrijetla vaskularnog endo-
tela (VEGF) i receptora za transformiraju}i factor rasta beta (TGFb-r) u obje vrste. Istra`ivanje je onuhvatilo 25 slu~a-
jeva HCC u ljudi i 8 slu~ajeva HCC u pasa. U ljudi se ovaj tumor u svim slu~ajevima pojavio u jetri zahva}enoj ciroti~nim
promjenama, dok je u pasa dio jetre nezahva}en tumorom bio nepromijenjen. U ljudi je u dva slu~aja utvr|ena infekcija
s virusom hepatitisa B, a u jednom s virusom hepatitisa C. Istra`ivanje je pokazalo izostanak reakcija na TGFb-r u {est
tumora pasa, dok je ova reakcija izostala samo u jednom tumoru ljudi. Hepatocitni antigen Hep Par 1 je u ve}ini tumora
bio pozitivan sa zna~ajno smanjenim intenzitetom reakcije u usporedbi s normalnim hepatocitima, dok je CK19 spe-
cifi~an za bilijarni epitel bio negativan. Rezultati istra`ivanja ukazuju na zna~enje TGFb-r u nastanku HCC u pasa i
istodobno nagla{avaju njegovo zna~enje u ovom tumoru ljudi.
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